BB Biotech Q3 net profit falls, NAV underperforms biotech index

By Reuters News


Overview

  • Switzerland investment firm's Q3 net profit fell yr/yr as NAV underperformed biotech index

  • Three portfolio companies received US drug approvals during the quarter

  • Proceeds from two M&A deals were redeployed into twelve new positions


Outlook

  • BB Biotech expects further clinical and regulatory milestones across its portfolio in Q4

  • Company sees selective opportunities in companies with share price declines but unchanged clinical prospects

  • BB Biotech says sustained NAV performance relative to benchmark remains its investment progress measure


Result Drivers

  • CLINICAL PROGRESS - Three portfolio companies received US drug approvals in Q3, with additional positive clinical trial results reported across the portfolio

  • PORTFOLIO REDEPLOYMENT - Proceeds from two M&A transactions totaling CHF 280 mln were reinvested into twelve new positions spanning commercial-stage, clinical-stage and private companies

  • ACTIVE POSITION MANAGEMENT - Higher portfolio activity reflected completed acquisitions and valuation-driven adjustments, with eight positions exited and rebuilding of selected holdings at lower valuations


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Income

CHF 175 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the investment management & fund operators peer group is "buy"

  • The stock recently traded at 35 times the next 12-month earnings vs. a P/E of 23 three months ago


Reuters Recommended Reads

  • Oct 22 - Roche beats revenue estimates, shares slip as copycats eat into Xolair sales

  • Oct 22 - Galderma lifts outlook for second quarter in a row after sales jump

  • Oct 22 - Netherlands' Argenx Q3 sales jump on strong VYVGART demand


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.